Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Clinical neurodiagnostics

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Lenka Novakova; Henrik Zetterberg; Peter Sundström; Markus Axelsson; Mohsen Khademi; Martin Gunnarsson; Clas Malmeström; Anders Svenningsson; Tomas Olsson; Fredrik Piehl; Kaj Blennow; Jan Lycke

Originally published in Neurology · 2017-10-27

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Objective To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between NFL concentrations in serum and CSF in multiple sclerosis (MS). Methods NFL concentrations were measured in paired serum and CSF samples (n = 521) from 373 participants: 286 had MS, 45 had other neurologic conditions, and 42 were healthy controls (HCs). In 138 patients with MS, the serum and CSF samples were obtained before and after DMT treatment with a median interval of 12 months. The CSF NFL concentration was measured with the UmanDiagnostics NF-light enzyme-linked immunosorbent assay. The serum NFL concentration was measured with an in-house ultrasensitive single-molecule array assay. Results In MS, the correlation between serum and CSF NFL was r = 0.62 ( p p p p p p Conclusions Serum and CSF NFL levels were highly correlated, indicating that blood sampling can replace CSF taps for this particular marker. Disease activity and DMT had similar effects on serum and CSF NFL concentrations. Repeated NFL determinations in peripheral blood for detecting axonal damage may represent new possibilities in MS monitoring.

DISCUSSION

The data in this study are based on a large set of paired serum and CSF samples from a real-life cohort of patients across a wide clinical and therapeutic spectrum. They support serum NFL as a biomarker for monitoring disease activity and treatment intervention in MS. We found that serum and CSF NFL concentrations were highly correlated and reacted similarly during the different stages of MS and in response to treatment with DMTs. High serum and CSF NFL concentrations were associated with relapse and with the number of contrast-enhancing lesions on MRI.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?